Otitis Externa News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

KalVista Pharmaceuticals (KALV) and Tokai Pharmaceuticals (NASDAQ:NVUS) Critical Survey - The Ledger Gazette



KalVista Pharmaceuticals (KALV) and Tokai Pharmaceuticals (NASDAQ:NVUS) Critical Survey 
The Ledger Gazette
OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for ...

and more » 


Good Growth Opportunities in Global Otitis Externa Treatment Market till 2024 - MilTech



Good Growth Opportunities in Global Otitis Externa Treatment Market till 2024 
MilTech
Otitis externa causes inflammation of the external ear canal, which is a tube between ear and eardrum. The inflammation is caused due to infection in the ear canal which can be bacterial or fungal origin. Otitis externa is characterized by pain ...

and more » 


Otonomy's renaissance starts as Ménière's disease drug clears trial - FierceBiotech



BZ Weekly
 
Otonomy's renaissance starts as Ménière's disease drug clears trial 
FierceBiotech
... (ciprofloxacin) for children getting tympanostomy tubes for otitis media?continue to underperform and were just $300,000 in the third quarter. Otonomy is hoping Otiprio will gather momentum if it can claim an FDA approval for acute otitis externa ...
Otonomy's (OTIC) CEO David Weber On Q3 2017 Results - Earnings Call Transcript Seeking Alpha
Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX? in Patients with Ménière's Disease GlobeNewswire (press release)
Otonomy Lead Drug Succeeds in Late-Stage Study PharmaLive (press release)
Smarter Analyst  -Analyst Ratings  -Zacks Investment Research 
all 81 news articles » 


Ears, nose, and throat, oh, my! - ModernMedicine



Ears, nose, and throat, oh, my! 
ModernMedicine
Occam's razor will tell you that a child is unlikely to have both otitis externa and otitis media (OM) at the same time, and, because treating OM in older children is optional anyway,1 according to current guidelines, one can do just fine with only a ...

 


Ear fullness: Causes, symptoms, and treatments - Bel Marra Health



Bel Marra Health
 
Ear fullness: Causes, symptoms, and treatments 
Bel Marra Health
Otitis externa: Commonly referred to as swimmer's ear, it is characterized by inflammation of the ear canal?the tube running from the outer ear to the middle ear. Otitis externa can present with ear pain, swelling of the ear canal, and occasionally ...

 


Otomycosis (ear fungus): Causes, symptoms, treatment, and home remedies - Bel Marra Health



Bel Marra Health
 
Otomycosis (ear fungus): Causes, symptoms, treatment, and home remedies 
Bel Marra Health
Otomycosis is also called mycotic otitis externa or Singapore ear. The infection is usually on the external part of the ear. Aspergillus or Candida is commonly fungi associated with a fungus of the ear, but there are others. Most of the fungi are ...

 


Lots of Good News out for Otonomy Inc (NASDAQ:OTIC) - Stock News Union (blog)



Stock News Union (blog)
 
Lots of Good News out for Otonomy Inc (NASDAQ:OTIC) 
Stock News Union (blog)
FDA-approved OTIPRIO® (ciprofloxacin otic suspension) is used during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has ...

and more » 


Tokai Pharmaceuticals (NVUS) vs. Opiant Pharmaceuticals (NASDAQ:OPNT) Head-To-Head Review - The Ledger Gazette



Tokai Pharmaceuticals (NVUS) vs. Opiant Pharmaceuticals (NASDAQ:OPNT) Head-To-Head Review 
The Ledger Gazette
OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for ...

and more » 


Comparing Tokai Pharmaceuticals (NVUS) and The Competition - TrueBlueTribune



Comparing Tokai Pharmaceuticals (NVUS) and The Competition 
TrueBlueTribune
OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for ...

and more » 


Tokai Pharmaceuticals (NVUS) versus KalVista Pharmaceuticals (KALV) Critical Contrast - The Ledger Gazette



Tokai Pharmaceuticals (NVUS) versus KalVista Pharmaceuticals (KALV) Critical Contrast 
The Ledger Gazette
OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for ...

and more »